Egg Freezing Before Cancer Treatment: An Oncofertility Guide

A cancer diagnosis changes everything — and among the many fears that follow is the question of future fertility. For young women who have not yet had children, the prospect of treatment-induced infertility compounds an already devastating situation. The good news is that for most women, if action is taken before treatment begins, fertility preservation is possible — without compromising cancer treatment outcomes.

Oncofertility is the subspecialty that addresses exactly this: preserving reproductive options for cancer patients before gonadotoxic treatment. Solo Clinic has experience in rapid oncofertility cycles — completing egg or embryo freezing within the narrow time window that typically exists between a cancer diagnosis and the start of treatment.

How Cancer Treatment Threatens Fertility

Not all cancer treatments affect fertility equally. The main threats are:

• Chemotherapy with alkylating agents: Cyclophosphamide, busulfan, melphalan, chlorambucil, and procarbazine are the most gonadotoxic. They directly destroy primordial follicles — the irreplaceable resting pool of eggs — in proportion to dose and duration. Other chemotherapy agents (platinum compounds, taxanes, anthracyclines) carry lower but still significant gonadotoxic risk.
• Pelvic radiation: Direct radiation to or near the ovaries dramatically reduces follicle reserve. The ovarian radiation dose required to destroy 50% of the remaining primordial follicle pool decreases with age — younger women can tolerate slightly higher doses before permanent sterility results, but the risk is substantial even at moderate doses. Uterine radiation can also impair endometrial function and future pregnancy capacity.
• Ovarian surgery: Removal of ovarian tumours — even when benign — carries a risk of removing healthy ovarian cortex. Women facing repeated ovarian surgery should discuss fertility preservation before each operation.

Which Cancers Are Most Relevant?

Fertility preservation is most commonly discussed — and most frequently indicated — for:

• Breast cancer: The most common cancer in young Indian women. Chemotherapy regimens for breast cancer frequently include cyclophosphamide (the CMF and AC regimens), which is significantly gonadotoxic. Many breast cancers are hormone-receptor positive, raising concerns about oestrogen exposure during stimulation — addressed by modified protocols.
• Lymphoma (Hodgkin's and Non-Hodgkin's): BEACOPP and CHOP regimens contain highly gonadotoxic agents. Hodgkin's lymphoma particularly affects young women and has a high cure rate — making long-term quality of life, including fertility, a priority.
• Leukaemia: HSCT (haematopoietic stem cell transplant) conditioning regimens are among the most gonadotoxic of all treatments. Emergency egg freezing in the narrow pre-treatment window is critical.
• Cervical, ovarian, and uterine cancers: Depending on the treatment plan, fertility-sparing approaches may be discussed with the oncology team.
• Thyroid cancer: Radioactive iodine treatment carries some gonadal risk; fertility preservation discussion is appropriate for younger patients.

The Egg Freezing Process Before Cancer Treatment

The process is identical to social egg freezing — ovarian stimulation, monitoring, egg collection, and vitrification — but with two critical differences: urgency and protocol modification for hormone-sensitive cancers.

Urgency: The 2 to 4 Week Window

Most cancer treatment teams can allow 2 to 4 weeks for fertility preservation before commencing chemotherapy or radiation. This is usually sufficient to complete one egg collection cycle. In exceptional circumstances where even this delay is not possible, options include natural cycle egg collection (collecting whatever egg is naturally developing without stimulation) or ovarian tissue cryopreservation (surgical removal of ovarian cortex for storage — discussed in P5-8).

At Solo Clinic, we can begin an oncofertility stimulation cycle without waiting for the next natural menstrual period — random-start protocols allow stimulation to begin on any day of the cycle, reducing the total time required by up to 2 weeks.

Modified Protocols for Breast Cancer

Standard ovarian stimulation raises oestradiol to levels 10 to 20 times normal during the stimulation phase. For women with oestrogen-receptor positive (ER+) breast cancer, there was historically concern that this oestrogen exposure might stimulate residual cancer cells.

This concern has been addressed by the letrozole co-stimulation protocol: letrozole (an aromatase inhibitor) is taken alongside the gonadotrophin injections to suppress oestradiol levels during stimulation. Multiple large studies — including the landmark Oktay protocol data — confirm that this modified approach keeps oestradiol at near-physiological levels while still producing an adequate number of mature eggs, without worsening breast cancer-free survival or overall survival. Women with ER+ breast cancer can safely undergo egg freezing using this protocol.

How Many Eggs Can Be Expected?

The number of eggs collected in an oncofertility cycle is the same as in any IVF stimulation cycle — determined by the woman's age and ovarian reserve at the time of the procedure. For a 28-year-old with good reserve, 10 to 14 mature eggs per cycle is a reasonable expectation. For a 36-year-old with normal reserve, perhaps 6 to 10. Reserve and yield are not changed by the cancer diagnosis itself — unless there has already been previous gonadotoxic treatment.

One cycle may or may not produce enough eggs to reach the target for the woman's age. When time allows, two cycles can be completed before treatment begins. Where only one cycle is possible, the yield from that cycle — however many eggs it produces — represents the available preserved material.

What Happens After Cancer Treatment

After completing cancer treatment and being declared medically fit for pregnancy — a timeline that varies by cancer type (typically 2 to 5 years post-treatment for breast cancer, often shorter for lymphoma) — the frozen eggs can be warmed, fertilised with ICSI, and the resulting embryos transferred.

Success rates depend primarily on the woman's age at the time of freezing and the number of eggs collected. Live birth rates from oncofertility-preserved eggs are comparable to those from elective egg freezing at the same age. The oncology team's approval that pregnancy is medically safe is a prerequisite before use.

Frequently Asked Questions

Q1. Will egg freezing delay my cancer treatment?

In most cases, no — or only minimally. An oncofertility stimulation cycle takes 10 to 14 days of stimulation, with egg collection on approximately day 12 to 15. For the majority of solid tumours (breast cancer, lymphoma), a 2 to 4 week delay is medically safe and does not compromise treatment outcomes. Haematological cancers requiring urgent treatment (acute leukaemia) may not allow even 2 weeks — in these cases, ovarian tissue freezing or natural cycle egg collection are discussed.

Q2. I have already started chemotherapy. Is it too late?

It depends on the regimen and timing. Some cycles of chemotherapy leave residual follicles that can still be stimulated. For women mid-treatment, ovarian reserve testing is worthwhile to assess what remains. After treatment, if some reserve persists (detectable AMH), stimulation may be possible. The options are genuinely more limited, but are not always zero. A specialist assessment is the first step.

Q3. Should I freeze eggs or embryos before cancer treatment?

If you have a partner and are certain you wish to use their sperm, embryo freezing may offer marginally better per-unit success rates — embryos survive freeze-thaw better than eggs and are developmentally more robust. If you are single or wish to preserve flexibility in your reproductive choices (including using donor sperm in the future), egg freezing maintains more options. Both are excellent choices with modern vitrification; the decision is largely personal.